Clinical Research Directory

Inclusion Criteria: * Histological detection confirmed CD19/CD20/CD22/CD30 postive non-Hodgkin lymphoma * Recieved more than 2 lines of chemotherapy * With contraindications of hematopoietic stem cell transplantation or relapse after hematopoietic stem cell transplantation * Expected survival more than 3 months * Karmofsky performance score ≤ 60, and ECOG ≥ 2. * Enough organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT \< 2 × upper limitation of normal; SpO2 \> 92% * CBC results: Hb ≥ 80g/L, ANC \> 1 × 10E9/L, Plt ≥ 50 × 10E9/L * Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion * With measurable disease * Written informed consent could be acquired Exclusion Criteria: * Received immunol suppression treatment or steroids in recent 1 week before recruitment * Uncontrolled infection * HIV positive patients * Active HBV or HCV infection * Women in pregnancy and lactation * Refuse to conception control during treatment and 1 year after CAR-T infusion * Uncured malignancies other than non-Hodgkin lymphoma * Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma * Inheritated immune deficiancy * Severe heart disease